Pan-negative型非小细胞肺癌的研究进展  

Research Advances of Pan-negative Type of Non-small Cell Lung Cancer

作　　者：孙丽[1] 熊志成 韩琤波[1] Li SUN;Zhicheng XIONG;Chengbo HAN(Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110022, China)

机构地区：[1]中国医科大学盛京医院肿瘤内科,沈阳110022

出　　处：《中国肺癌杂志》2018年第2期129-138,共10页Chinese Journal of Lung Cancer

摘　　要：近年来随着对肿瘤驱动基因的不断探索和分子检测技术的快速发展,在非小细胞肺癌(non-small cell lung cancer,NSCLC)领域,一系列的驱动基因如EGFR、KRAS、BRAF、PIK3CA、ALK和ROS-1等相继被发现,并逐渐研发出相应的针对特定驱动基因变异的靶向治疗药物,使NSCLC患者的生存得到极大改善。尽管如此,仍有部分NSCLC患者未能检测到任何已知驱动基因变异,称之为pan-negative型NSCLC。本文就pan-negative型NSCLC的概念、临床病理和流行病学特点以及治疗预后等作一综述。In recent years, series of driver genes, such as EGFR, KRAS/NRAS, BRAF, PIK3CA, ALK and ROS1 and so on, have been found in non-small cell lung cancer （NSCLC） one after another with the development of molecular detect- ing technology. Targeted drugs bring benefits for these NSCLC patients with driver gene variations. However, some NSCLC did not have any known driver gene variations; we called it pan-negative lung cancer. In this paper, we summarize the concept, clinical pathological characteristics, the epidemiological characteristics, treatment and prognosis of pan-negative NSCLC.

关 键 词：肺肿瘤 驱动基因 Pan-negative 

分 类 号：R734.2[医药卫生—肿瘤]